Description

Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)—-C34H47N11O9S2.xC2HF3O2—-[1]Chen H, et al. Safety, pharmacokinetic and pharmacodynamic studies of batifiban injection following single- and multiple-dose administration to healthy Chinese subjects. J Huazhong Univ Sci Technolog Med Sci. 2009 Feb;29(1):12-8. [Content Brief]—-817.94 (free base)–99.58–O=C(N1[C@@](C(N[C@@H](CSSCCC2=O)C(N)=O)=O)([H])CCC1)[C@@H](NC([C@@H](NC(CNC([C@@H](N2)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC3=CNC4=CC=CC=C34.OC(C(F)(F)F)=O.[x]–Cardiovascular Disease–10 mM in DMSO–Glycoprotein VI—-Immunology/Inflammation–Peptides